Vardenafil HydrochlorideThird Party Manufacturing in India

Vardenafil Hydrochloride is a potent and highly selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant phosphodiesterase enzyme in the human corpus cavernosum.

During sexual stimulation, local release of nitric oxide from nerve terminals and endothelial cells in the corpus cavernosum activates guanylate cyclase, which catalyzes the synthesis of cGMP. This second messenger triggers relaxation of smooth muscle cells in the corpus cavernosum and penile arterioles, allowing increased blood flow into the penis and producing an erection. PDE5 normally terminates this signal by degrading cGMP.

Vardenafil competitively inhibits PDE5 at its catalytic site, preventing the breakdown of cGMP and allowing its accumulation in smooth muscle cells. This prolongs the duration of smooth muscle relaxation and enhances erectile response to sexual stimulation. Importantly, vardenafil has no direct relaxant effect on the corpus cavernosum in the absence of sexual stimulation, as it requires the initial nitric oxide signal to function.

Vardenafil is approximately ten-fold more potent than sildenafil at inhibiting PDE5, with a faster onset of action reaching peak plasma concentrations within one hour. Its selectivity for PDE5 over PDE6 is approximately 15-fold, which correlates with a lower incidence of visual side effects. The drug is metabolized primarily by hepatic CYP3A4 and exhibits a half-life of four to five hours.

Therapeutic Uses

Vardenafil is prescribed for the treatment of:

• Erectile Dysfunction (ED): The primary FDA-approved indication. Vardenafil 20 mg tablets restore erectile function in men with ED of organic, psychogenic, or mixed etiology, including those with diabetes, hypertension, and post-prostatectomy ED.
• Premature Ejaculation: Emerging evidence supports off-label use for significantly increasing intravaginal ejaculatory latency time in men with premature ejaculation.
• Pulmonary Arterial Hypertension: Investigational use as a monotherapy or combination therapy for PAH, leveraging the vasodilatory effects of PDE5 inhibition in pulmonary vasculature.

Why Manufacturers Choose Vardenafil Hydrochloride

Vardenafil is a well-established PDE5 inhibitor with a strong global brand presence as Levitra. It offers a differentiated profile from sildenafil and tadalafil with faster onset and high potency, making it a preferred choice for specific patient populations. The 20 mg tablet is the most widely prescribed strength worldwide.

India is a major manufacturer of generic PDE5 inhibitors, with well-established API supply chains and export infrastructure for regulated markets. Vardenafil tablets are manufactured using conventional wet granulation or direct compression technologies, compatible with high-speed production lines.

This makes Vardenafil Hydrochloride an attractive molecule for third party manufacturing in India, with consistent demand from domestic PCD franchise partners and international export buyers in the Middle East, Africa, and Southeast Asia.